BioCryst Reports Q3 2026 Revenue of $180.3 Million

Lyell Immunopharma Announces $80M Private Placement Lyell Immunopharma says the private placement will advance Ronde-Cel toward a planned BLA submission. M impact | EQUITY | Nov 04, 2026, 02:09 PM UTC

InnovAge Reports Fiscal Q1 2027 Revenue of $264.8 Million Revenue rose 12.1% year over year and income before taxes increased 153.1% to $20.0 million. Diluted EPS was $0.14 versus analyst expectations of $0.09. Fiscal 2027 revenue guidanc M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC

TXO Partners Reports Third-Quarter Revenue of $55.1 Million Revenue fell 45% year over year, primarily due to a $68.3 million adverse swing in derivative results. The company reported a $32.1 million net loss, versus net income of $4.4 mill M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC

Flowco Reports Third-Quarter 2026 Revenue of $258.6 Million Flowco reported net income of $40.7 million, adjusted EBITDA of $103.9 million and free cash flow of $72.4 million. Diluted EPS was $0.40, above the FactSet consensus estimate of $ M impact | EQUITY | Nov 04, 2026, 02:03 PM UTC

Spartan Delta Reports Q3 Results, Raises 2026 Capital Plan and Sets 2027 Guidance Third-quarter Adjusted Funds Flow was $109.5 million, up 117% year over year, on production of 53,448 BOE/d and record 46% liquids weighting. Spartan raised its 2026 capital progra M impact | EQUITY | Nov 04, 2026, 02:02 PM UTC

European session market picture: S&P 500 +1.17%, Nasdaq 100 +0.35%; EUR/USD +0.63%, WTI -2.92%, LLOY leads volume European session market picture. US index futures: S and P futures is up 1.17 percent, Nasdaq futures is up 0.35 percent, Dow futures is up 2.22 percent and Russell futures is up 1 M impact | EQUITY | Nov 04, 2026, 02:02 PM UTC

BioCryst Reports Q3 2026 Revenue of $180.3 Million

Story updates

Related stories